文献速递皮肤肿瘤

术前使用溴莫尼定0.33%凝胶在Mohs显微描记手术中止血的随机对照初步研究

Randomized controlled pilot study of the preoperative use of brimonidine 0.33% topical gel for hemostasis in Mohs micrographic surgery.
PubMed 文献 · J Am Acad Dermatol · 2017-10-12

该随机对照初步研究评估了术前局部应用溴莫尼定0.33%凝胶对服用抗凝药并接受Mohs显微描记手术(MMS)患者的止血效果。研究将受试者随机分为对照组(n=10)和研究组(n=14),研究组在标准治疗基础上术前应用溴莫尼定。结果显示,治疗组30秒内失血量较对照组减少68%(P < .05),且治疗组无患者 wound bed 烧灼面积超过50%,而对照组为80%;治疗组红斑减少3.89倍(P < .01)。结论提示术前应用溴莫尼定0.33%凝胶可能有助于减少服用抗凝药患者MMS期间的失血和电灼需求。

要点

  • 术前应用溴莫尼定0.33%凝胶可使服用抗凝药患者MMS术中30秒失血量减少68%。
  • 治疗组无患者烧灼面积超过50%,对照组为80%。
  • 治疗组红斑较对照组减少3.89倍。

核心结论

  • 术前应用溴莫尼定0.33%凝胶可能有助于减少服用抗凝药患者MMS期间的失血和电灼需求。

研究设计与样本

  • 随机对照初步研究,受试者为服用抗凝药并接受MMS的患者,随机分为对照组(n=10)和研究组(n=14)。
  • 对照组接受标准MMS,研究组在标准MMS基础上术前应用溴莫尼定。

主要发现

  • 治疗组30秒内失血量较对照组减少68%(P < .05)。
  • 治疗组无患者 wound bed 烧灼面积超过50%,对照组为80%。
  • 治疗组红斑较对照组减少3.89倍(P < .01)。

临床怎么用

  • 对于服用抗凝药并接受MMS的患者,可考虑术前应用溴莫尼定0.33%凝胶以减少术中失血和电灼需求。

局限性

  • 样本量小;部位仅限于面部;出血测量未考虑麻醉药与血液混合;烧灼面积百分比为视觉估计;未测量麻醉体积、伤口深度或术后并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brimonidine topical gel may be useful in cutaneous surgical procedures because of its vasoconstricting properties. OBJECTIVE: Assess the hemostatic effect of topically applied brimonidine in patients being treated with anticoagulants and undergoing Mohs micrographic surgery (MMS). METHODS: Subjects undergoing MMS were randomly assigned to the control (n = 10) or study arm (n = 14). Controls received standard-of-care MMS, whereas the study arm received the same and preoperative application of brimonidine. Evaluations included rate of blood flow, percentage of wound bed surface area needing electrocautery, and changes in skin colorimeter readings. RESULTS: The treatment arm had 68% less blood loss over 30 seconds versus the control arm (P < .05). No patient in the brimonidine arm had more than 50% of the wound bed cauterized versus 80% in the controls. Erythema in the treatment arm was decreased by 3.89 times (P < .01) versus in the control arm. LIMITATIONS: Limitations were small sample size; sites limited to the face; the fact that measurement of bleeding did not account for anesthetic mixed with blood; visual estimation of percentage of wound surface area requiring cauterization; and no measurement of volume of anesthesia, wound depth, or postoperative complications. CONCLUSION: Preoperative application of brimonidine 0.33% gel may help decrease blood loss and the need for electrocautery during MMS for patients taking anticoagulants.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Chen E, Patel RA, Kwak YJ, et al. Randomized controlled pilot study of the preoperative use of brimonidine 0.33% topical gel for hemostasis in Mohs micrographic surgery. J Am Acad Dermatol. 2017. PMID: 29031658. doi:10.1016/j.jaad.2017.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。